Loading clinical trials...
Loading clinical trials...
A Phase I Study to Assess the Effect of a CYP3A Inducer (Rifampin) on the Pharmacokinetics of ABT-263 (Navitoclax)
Conditions
Interventions
navitoclax
Rifampin
Start Date
May 1, 2010
Primary Completion Date
May 1, 2011
Completion Date
May 1, 2011
Last Updated
November 21, 2017
NCT06898450
NCT06658951
NCT05101070
NCT05719558
NCT06307795
NCT06716138
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions